Skip to main content

Neurogene Inc.

corporate_fare Company Profile

Neurogene Inc.

NGNE·NASDAQ·Life Sciences·CIK 0001404644

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases that are not treatable by conventional gene therapy. The company aims to address the challenges of complex neurological disease biology and variable gene uptake and expression. Neurogene Inc. utilizes its proprietary transgene regulation technology, EXACT™ (Expression Attenuation via Construct Tuning), which employs microRNA-based genetic circuits. This technology is designed to deliver therapeutic levels of transgenes to specific brain areas involved in neurological disease pathology. Neurogene Inc.'s primary clinical-stage program is NGN-401, which is being developed for the treatment of Rett syndrome. NGN-401 uses the EXACT technology and adeno-associated virus (AAV) delivery. Rett syndrome is a severe and progressive neurodevelopmental disease causing significant neurological and physical impairment. The company's ongoing registrational trial for NGN-401, named Embolden™, is a single-arm, open-label, baseline-controlled trial. This trial is evaluating the 1E15 vg dose of NGN-401 in 20 females with Rett syndrome, aged three and above. Embolden has enrolled 100% of participants, and more than 50% of participants have been dosed. Dosing is expected to be completed in the second quarter of 2026. Neurogene Inc. also completed dosing in a Phase 1/2 open-label, multi-center clinical trial of NGN-401 for Rett syndrome, where ten participants received the 1E15 vg dose. NGN-401 is administered via a one-time intracerebroventricular (ICV) procedure.

Neurogene Inc. (NASDAQ:NGNE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for NGNE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for NGNE spans 10-Q, 8-K, 424B5, 10-K.

Recent high-impact activity:

  • Neurogene Q3 10-Q: $94.4M Nine-Month Loss, $359.7M Cash Into Q1 2029
  • Neurogene Posts $29.0M Q3 Loss, $359.7M Cash Through Q1 2029, Embolden Data 2H 2027
  • Neurogene Q2 Loss Widens but Cash Runway Extended to 2029; PPQ Campaign Initiated
  • Neurogene Reports Q2 2026 Results, Extends Cash Runway into 2029, and Initiates PPQ Campaign for NGN-401
  • Neurogene Initiates PPQ Campaign, Extends Cash Runway to 2029 After Q2 Results

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$90.35M
Diluted EPS
-$4.24
Op. Cash Flow
-$77.17M
Free Cash Flow
-$78.36M
Operating Income
-$103.33M
Cash & Equivalents
$103.84M
Debt / Equity
0.00×
Shares Outstanding
15.49M sh
Source: 10-K · filed 2026-03-24 · accession 0001404644-26-000019

Short Interest & Short Volume

16.95 days to cover

FINRA reported short interest of 5,685,998 shares in NGNE as of the October 30, 2026 settlement, a 11.6% increase from the prior period — about 16.9 days to cover at its recent average daily volume. On November 20, 2026, 70.2% of NGNE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,685,998 shares as of October 30, 2026
Change vs prior period▲ 11.6%
Days to cover16.95 at avg daily volume of 335,519
Daily short volume (FINRA facilities)70.2% of 60,325 shares on November 20, 2026
5-day average short volume56.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for NGNE, detected from its recent SEC filings · based on capital-structure filings through 2026-07-01.

1 recent capital raiseATM program

Public Offering Priced · Significant Capital Raise

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with N →
$22.15
52-week range · as of 2026-11-09 $15.93 – $43.66
Market cap
$458.53M
Volume
178.3K (0.6× avg)
3-mo avg 316.4K
Live data · 2026-11-22 12:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NGNE - Latest Insights

NGNE
Nov 09, 2026, 4:02 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $26.00
Real-time Price: $22.15 info
Change: -$3.85 (-15%) info
Market Cap: $458.525M info
NGNE
Nov 09, 2026, 8:19 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.31
Real-time Price: $22.15 info
Change: -$3.16 (-12%) info
Market Cap: $458.525M info
NGNE
Aug 11, 2026, 4:57 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $35.80
Real-time Price: $22.15 info
Change: -$13.65 (-38%) info
Market Cap: $458.525M info
NGNE
Aug 11, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.21
Real-time Price: $22.15 info
Change: -$14.06 (-39%) info
Market Cap: $458.525M info
NGNE
Aug 11, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $36.21
Real-time Price: $22.15 info
Change: -$14.06 (-39%) info
Market Cap: $458.525M info
NGNE
Jul 02, 2026, 6:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $31.97
Real-time Price: $22.15 info
Change: -$9.82 (-31%) info
Market Cap: $458.525M info
NGNE
Jul 01, 2026, 8:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.97
Real-time Price: $22.15 info
Change: -$9.82 (-31%) info
Market Cap: $458.525M info
NGNE
Jul 01, 2026, 7:58 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $31.97
Real-time Price: $22.15 info
Change: -$9.82 (-31%) info
Market Cap: $458.525M info
NGNE
Jul 01, 2026, 8:44 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $30.90
Real-time Price: $22.15 info
Change: -$8.75 (-28%) info
Market Cap: $458.525M info
NGNE
Jun 30, 2026, 4:19 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $29.90
Real-time Price: $22.15 info
Change: -$7.75 (-26%) info
Market Cap: $458.525M info
NGNE
Jun 30, 2026, 4:02 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $26.80
Real-time Price: $22.15 info
Change: -$4.65 (-17%) info
Market Cap: $458.525M info
NGNE
Jun 29, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $33.00
Real-time Price: $22.15 info
Change: -$10.85 (-33%) info
Market Cap: $458.525M info
NGNE
Jun 29, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $33.00
Real-time Price: $22.15 info
Change: -$10.85 (-33%) info
Market Cap: $458.525M info
NGNE
Jun 08, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $26.49
Real-time Price: $22.15 info
Change: -$4.34 (-16%) info
Market Cap: $458.525M info
NGNE
May 12, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $31.54
Real-time Price: $22.15 info
Change: -$9.39 (-30%) info
Market Cap: $458.525M info
NGNE
May 12, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.54
Real-time Price: $22.15 info
Change: -$9.39 (-30%) info
Market Cap: $458.525M info
NGNE
May 12, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.54
Real-time Price: $22.15 info
Change: -$9.39 (-30%) info
Market Cap: $458.525M info
NGNE
Apr 20, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $27.50
Real-time Price: $22.15 info
Change: -$5.35 (-19%) info
Market Cap: $458.525M info
NGNE
Mar 24, 2026, 4:04 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $20.90
Real-time Price: $22.15 info
Change: +$1.25 (+6%) info
Market Cap: $458.525M info
NGNE
Mar 24, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.36
Real-time Price: $22.15 info
Change: +$2.79 (+14%) info
Market Cap: $458.525M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets